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VEGF was discovered almost 25 years ago, and its angiogenic activity has been extensively studied ever since. Accumulating evidence indicates,
however, that VEGF also has direct effects on neuronal cells. VEGF exerts neuroprotective effects on various cultured neurons of the central nervous
system. In vivo, VEGF controls the correct migration of facial branchiomotor neurons in the developing hindbrain and stimulates the proliferation of
neural stem cells in enriched environments and after cerebral ischemia. Transgenic mice expressing reduced levels of VEGF develop late-onset motor
neuron degeneration, reminiscent of amyotrophic lateral sclerosis (ALS), whereas reduced levels of VEGF have been implicated in a polyglutamine-
induced model of motor neuron degeneration. Recent data further reveal that intracerebroventricular delivery of recombinant VEGF protein delays
disease onset and prolongs survival of ALS rats, whereas intramuscular administration of a VEGF-expressing lentiviral vector increases the life
expectancy of ALSmice by asmuch as 30%. Deciphering the precise role of VEGF at the neurovascular interface promises to uncover new insights into
the development and pathology of the nervous system, helpful to design novel strategies to treat (motor) neurodegenerative disorders.
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and nerve fibers are highly branched in stereotyped patterns and
often course along each other throughout the body. Today, evi-
dence emerges that vessels, which arose later in evolution than
nerves, appear to have co-opted the same genetic pathways to
develop their functionally distinct, but architecturally similar
network [1,2]. Another exciting discovery is that vessels and
nerves crosstalk. In some cases, vessels produce signals that attract
axons to track alongside the pioneer vessel, in other cases, nerves
produce signals to guide blood vessels [1,2]. Perhaps the best
illustration of how such crosstalk affects vessels and neurons in
health and disease is provided by the activities of vascular
endothelial growth factor (VEGF) and its receptors.
1. VEGF, a key angiogenic player
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doi:10.1016/j.bbadis.2006.04.005distinguishes itself from other angiogenic factors by a unique
combination of properties. Indeed, VEGF is produced and re-
leased by cells in close vicinity to endothelial cells [3,4] and, after
bindingVEGF receptor-1 (VEGFR-1, Flt1), VEGFR-2 (Flk1) and
neuropilins (Nrp1; Nrp2), VEGF induces endothelial cells to
proliferate, migrate, survive, and assemble into an interconnected
vessel network (Fig. 1) [5]. VEGF is transcribed from a single
gene into various isoforms (amongwhichVEGF121, VEGF165 and
VEGF189). Because of their different affinities for extracellular
matrix components and receptor subtypes, these isoforms provide
a spatial gradient, critical for vessel patterning [6]. The pre-
dominant role of VEGF is illustrated by the fact that loss of even a
single allele in the mouse results in haploinsufficiency with early
embryonic lethality due to severe vascular defects [7,8]. Addi-
tional tissue-specific and conditional inactivation studies ofVEGF
revealed that VEGF is absolutely required for the formation of the
heart and the large vessels that connect with the heart [9] but also
for vascular expansion of various organs in the body during
postnatal growth (e.g., kidney [10], bone [11], and retina [6]). The
adult vasculature seems to be less critically dependent on VEGF,
although it still requires low maintenance levels of VEGF.
Fig. 1. Ligands and receptors of the VEGF family. Over the last few years, several molecules structurally related to VEGF have been identified, including placenta growth
factor (PlGF), VEGFB,VEGFCandVEGFD.All these ligands bind and activate the same receptors, althoughwith different affinities. VEGF is transcribed from a single gene
into various isoforms (VEGF121,VEGF164, andVEGF189), exhibiting distinct receptor specificities. ThreeVEGF tyrosine kinase receptors have been identified:VEGFR-1
(or Flt1), VEGFR-2 (or Flk1), and VEGFR-3 (or Flt4). Neuropilins 1 and 2 (Nrp1 and Nrp2) are another class of high-affinity non-tyrosine kinase receptors for VEGF.
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angiogenesis in pathological conditions: VEGF mRNA is
markedly upregulated in the vast majority of human tumors,
while occlusion of the left anterior descending coronary artery
results in a dramatic increase in VEGF levels in the pig myocar-
dium [12]. Presently, both therapeutic angiogenesis using recom-
binant VEGF and VEGF gene transfer (for the treatment of
coronary or limb ischemia) and inhibition of VEGF-mediated
tumor vascularization are actively being pursued clinically [12].
Two years ago, an anti-VEGF antibody was approved as the first
successful angiogenesis inhibitor for the treatment of colorectal
cancer, underlining the overall feasibility of angiogenesis
inhibition strategies [13].
2. Neural-derived VEGF guides the neurovasculature
The vasculature of the central nervous system (CNS)
undergoes considerable angiogenesis in both the fetus and
premature infant to support blood supply to the rapidly
developing cortex until reaching its normal density in
adulthood. This process is controlled by a strict temporal and
spatial-regulated expression of VEGF by neurons and glia cells
in the brain [4,14–16]. Initially, VEGF is expressed by neurons
of the outer cortex layers, but as development proceeds, VEGF
expression progresses to the deeper layers of the cortex. Cortical
vascularization proceeds in a similar fashion with vessels
starting from meningeal layers early in development but then
penetrating to deeper (VEGF-expressing) cortical layers to form
the dense vascular network seen at later stages. Interestingly,
glial expression of VEGF coincides with the time at which glial
end feet begin to invest blood vessels. Glial cells may thus
produce the VEGF signals required to maintain the vasculature.
The importance of neural-derived VEGF is illustrated by
findings that neuronal inactivation of VEGF in the early em-bryonic mouse brain impairs angiogenesis and causes neuronal
degeneration of cerebral structures such as the hippocampus
[17,18]. Neuronal inactivation of the main VEGF receptor, Flk1,
did not result in an overt phenotype during neural development,
suggesting that in these mice, VEGF affected neural development
primarily by affecting vascular development [17]. Mice over-
expressing VEGF in neurons exhibited increased densities of
vessels in the cerebral cortex, thereby confirming that neuron-
derived VEGF is a critical parameter determining the density of
the vasculature in the developing CNS [19]. VEGF also provides
positional cues directing the growth of capillaries towards the
ventricular zone, since loss of the normal VEGF gradient in mice
expressing only the VEGF121 isoform leads to impaired growth of
blood vessels towards the midline of the developing hindbrain
[20]. The role of VEGF within the central nervous system is
however not restricted to its effect on the vasculature as VEGF is
also involved in other aspects of neurodevelopment (see further
below).
During normal development, the specification of endothelial
cells in the arteries in some peripheral tissues is co-determined by
the presence of nerves. This leads to an intimate neurovascular
association, such as for instance in the skin of the embryonic limb,
where arteries follow the branching pattern of nerves, while veins
do not [21]. In mutant embryos lacking sensory nerves (neuro-
genin 1 and 2 homozygous mutants are characterized by a virtually
complete absence of peripheral nerves), arteries fail to properly
differentiate, while in embryos with a disorganized patterning of
nerves (in mice lacking semaphorin 3A, the pattern of peripheral
nerve growth is completely disorganized, axons appear more
fasciculated and are less finely branched), the trajectory of blood
vessel branching is also altered and, remarkably, follows that of the
misrouted nerves [21]. In vitro, VEGF expressed by sensory neu-
rons and Schwann cells induces arterial marker expression in
isolated endothelial cells, suggesting that peripheral nerves
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differentiation in the skin via local secretion of VEGF [21].
Consistently, VEGF administration or inhibition of VEGF signal-
ing using soluble Flt1 perturbed vascularization of developing
forelimbs in quail embryos, but had little effect on the pattern of
innervation [22]. Likewise, inhibition of Flk1 or VEGF sequestra-
tion using soluble Flt1 had no effect on axonal outgrowth in
embryonic DRG explants, while connectivity, branching and
structural integrity of the capillary network were severely disrupted
[23]. However, when VEGF signaling from nerves to vessels is
disrupted – as accomplished by intercrossing floxed VEGF mice
with Wnt1-Cre mice, which express the Cre recombinase in both
sensory nerves and peripheral glia – the expression of arterial
markers was strongly reduced, although nerve-vessel alignment
itself was apparently unperturbed [24]. Although the latter obser-
vation suggests that additional factors are necessary for the correct
alignment between arteries and nerves, nerve-derived VEGF
appears to be essential for the specification of arteries in the skin of
the embryonic limb [24].
3. The duality of neuropilins implicates VEGF in neural
patterning
Neuropilins are 130- to 140-kDa cell-surface receptors with
short intracellular domains insufficient for the independent trans-
duction of biological signals [25]. They have been implicated in
vessel patterning because they are receptors of specific VEGF
isoforms (Fig. 1) [26]. Neuropilins co-assemble with the VEGF
receptor Flk1 and thereby enhance the proliferation and migration
of endothelial cells in response to VEGF. Concomitantly, zebra-
fish ormice lackingNrp1 exhibit branching and remodeling defects
of vessels [27,28]. Neuropilins are also receptors for the sema-
phorins, which are secreted repellent factors involved in neuronal
guidance [29–31]. They serve as co-receptors for receptors
belonging to the plexin family and as such plexin/neuropilin
complexes are able to transduce semaphorin-mediated repulsion
[32,33]. Consequently, mice lacking Nrp1 suffer also from a
severely disorganized neural development [34]. Mice expressing a
variant Nrp1, only capable of binding VEGF but not semaphorins,
do not exhibit vascular defects, suggesting that the vascular role of
Nrp1 is mediated by the binding of VEGF to Nrp1 [35].
The neuronal role of Nrp1, on the other hand, seems to be
mediated both by semaphorins and VEGF. Recent evidence
indicates that VEGF and its co-receptor Nrp1 are required for the
migration of facial branchiomotor neurons [36]. Facial branchio-
motor neurons are born in a ventral position of the hindbrain
segment termed rhombomere 4 and then move their somata
caudally to travel through rhombomere 5 and into rhombomere 6.
This migration spans several days, covers many cell diameters,
and culminates in the formation of the paired motor nuclei of the
VIIth cranial (facial) nerve, which control the movement of the
facial musculature. In mice lacking Nrp1, the migration of facial
branchiomotor neuron somata was compromised, resulting in the
formation of misshapen and mal-positioned facial motor nuclei
[36]. VEGF controlled the migration of soma of facial branchio-
motor neurons by interacting with Nrp1 but was not required for
their axon guidance [36]. Instead, semaphorine 3A was essentialfor axonal guidance, but not for the pathfinding of the somata of
the branchiofacial motor neurons [36]. These observations
demonstrate, for the first time, that VEGF contributes to neuronal
patterning in vivo, and that different compartments of one cell can
be co-ordinately patterned by structurally distinct ligands for a
shared receptor.
In zebrafish, the segmental outgrowth of axons and somata
from primary motor neurons in the trunk is alsomediated by Nrp1
[37]. Indeed, knockdown ofNrp1 bymorpholino oligonucleotides
induces aberrant branching of motor axons, additional exit points
of motor axons from the trunk andmigration of motor neurons out
of the spinal cord [37]. Co-injection of semaphorin3A or VEGF-
directed morpholinos with Nrp1 morpholinos at a concentration
not inducingmotor axon ormotor neuron outgrowth defects when
injected alone did induce significant defects [37]. Nrp1 in primary
motor neurons may thus integrate signals from several ligands,
including semaphorin3A and VEGF, and are needed for proper
segmental growth of primary motor neuron cell bodies and nerves
in zebrafish. In conclusion, VEGF seems to play an important role
as a guidance molecule, not only on the developing vasculature,
but also during neurodevelopment.
4. The VEGF system in invertebrates
VEGFand its receptors appeared first in evolution in the central
nervous system (CNS) of species, such as the worm and fruitfly,
which lack a well-developed vascular system. In the Caenorhab-
ditis elegans genome, there is a family of four tyrosine kinase
receptors, which are structurally related to VEGF receptors [38].
The common expression sites of these receptors (Vascular Endo-
thelial growth factorReceptor or ver genes) are specialized cells of
neural origin: ver-1 is expressed in the support (glial) cells of
amphid and phasmid neurons, ver-2 in chemosensorial neurons,
and ver-3 in the ALA neuron of the dorsal ganglia. In the fruit fly
Drosophila melanogaster, the hemocytes (or primitive blood
cells) express a receptor tyrosine kinase, related to mammalian
PDGF and VEGF Receptors (PVR) [39,40]. This receptor is
required for hemocytes to migrate in response to three VEGF
orthologs, which are expressed along hemocyte migration routes.
Loss of PVR function also causes defects in axon tract morpho-
logy and in positioning of glial cells. VEGF and its receptors thus
seem to have originated from the central nervous system.
5. Neuroprotective activities of VEGF
Recent in vitro findings revealed that VEGF has direct effects
on a variety of neuronal cell types. For instance, VEGF increases
the survival of cultured hippocampal, cortical, cerebellar, granule,
dopaminergic, autonomic and sensory neurons under various
conditions of stress (reviewed in [41–43]). In general, the survival
activity of VEGF relies on the same tyrosine kinase receptors and
downstream protein kinases described previously in non-neural
tissues, including activation of mitogen-activated protein kinases
(MAPKs), phosphatidylinositol 3-kinase (PI3K)/Akt, and Rho/
Rac, and suppression of the pro-apoptotic caspase-3 [44]. When
applied to primary cortical neurons, VEGF increases the ex-
pression of the neuronal microtubule markers TUJ1 and MAP-2,
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structural stability of neurons [45]. VEGF protects NSC34 motor
neuron-like cells against hypoxia and oxidative-stress-induced
apoptosis—an effect, blocked by a combination of anti-Nrp1 and
anti-Flk1 antibodies [46], as well as primary motor neuron cul-
tures under basal conditions and after hypoxia/hypoglycemia-
induced cell death [47]. Notably, intrathecal infusion of Flk1
antisense oligonucleotides in rats, followed by a hypoxic challenge
for 7 days, results in approximately 50% loss of motor neurons
[48].
6. Effects of VEGF on other neural cell types
VEGF also affects other neural cell types. For instance, VEGF
has mitogenic effects on astrocytes, in mesencephalic explant
cultures [49] and following intracerebral VEGF delivery in vivo
[50]. Most astrocytes express the VEGF receptor Flt1, while
immunoexpression for the Flk1 receptor is absent [51]. VEGF
administration to fetal and postnatal cortical organotypic explant
cultures cause a significant increase in astroglial proliferation and
a dose-dependent increase in GFAP and nestin immunoreactivity,
whereas co-treatment with antisense oligonucleotides to Flt1
results in a dramatic decrease in GFAP and nestin immunoreac-
tivity, confirming the role of Flt1 inmediatingVEGF's gliotrophic
effects [51]. VEGF also induces proliferation ofmicroglia through
Flt1, both in the murine BV2 cell line as in primary microglial
cells, as well as chemotaxis in Boyden chamber assays [52].
VEGF also prolongs the survival and stimulates the proliferation
of Schwann cells in explant cultures of superior cervical and dorsal
root ganglia [53]. Schwann cells express Flt1, Flk1 and Nrp1, but
the effect of VEGF on Schwann cell migration appears to be
mediated by Flk1, as addition of a neutralizing antibody against
Flk1 completely blocks VEGF-induced migration [54]. Thus, the
direct effects of VEGF on neurons and Schwann cells are medi-
ated predominantly by Flk1 (and Nrp1), whereas the effects of
VEGF on astrocytes and microglia are directed by Flt1.
Besides its effects on differentiated neurons, VEGF also stimu-
lates neurogenesis in vitro and in vivo.As a competitive antagonist
of Sema3A for Nrp1 binding, VEGF also promotes the survival,
migration, and proliferation of neural stem cells [55]. After infusion
ofVEGF into the lateral ventricle of adult rats, the number ofBrdU-
positive neurons increases, not by stimulating the proliferation of
neural stem cell progenitors, but by preventing them to undergo
apoptosis [56]. Enriched environments, exercise and hippocampus-
dependent learning tasks stimulate neurogenesis [57]. VEGF, by
acting through Flk1, seems to mediate some of the enriched envi-
ronment effects on neurogenesis and cognition [57].
7. VEGF in ALS
Amyotrophic lateral sclerosis (ALS)–also termed Lou Geh-
rig's disease– is a progressive, adult-onset neurodegenerative
disorder characterized by degeneration and loss of large motor
neurons in the spinal cord, brainstem, and cerebral cortex, leading
to muscle atrophy, paralysis and death usually within 5 years after
onset of clinical symptoms (reviewed in [58–62]). ALS occurs
sporadically in 90% of cases, the remaining 10% being familial(FALS) [63]. Several types of familial ALS have been assigned to
loci of the human genome. ALS1, an autosomal dominant form of
adult ALS affects 14 to 23% of individuals with familial ALS and
is associated with more than 100 different mutations in the gene
encoding Cu/Zn superoxide dismutase (SOD1) on chromosome
21 [64]. Mutant SOD is generally believed to cause motor neuron
degeneration by gaining a toxic property [65]. Mice and rats,
expressing a mutant SOD1 transgene, develop ALS with clinical
and anatomo-pathological features, that are highly reminiscent of
those found in human ALS and are by far the most frequently
studied animal model for ALS [66,67]. However, the mechanisms
by which this toxic function causes ALS are still debated and
remain elusive [61]. Only very recently, additional genes
associated with familial ALS were discovered: (i) identical
missense mutations in the vesicle-trafficking protein VAPB gene
have been identified in families with atypical ALS (ALS8) [68];
(ii) homozygous mutations in ALSIN, a putative guanine nucleo-
tide factor for GTPase, have been found in a family with juvenile-
onset ALS (ALS2) [69,70] and (iii) missense mutations in sena-
taxin, a gene that encodes a novel DNA/RNA helicase, have been
found in autosomal dominant forms of juvenile ALS (ALS4) [71].
The genetic causes for the other forms of ALS are not yet known.
Recently, a novel role for VEGF in ALS was documented.
Mice with a subtle deletion of the hypoxia response element
(HRE), to which the hypoxia-inducible transcription factors
HIF-1α and HIF-2α bind, in the VEGF gene promoter
(VEGFδ/δ mice), produced insufficient VEGF levels leading
to adult-onset motor neuron degeneration, reminiscent of ALS
[46] (Fig. 2A, B). Many neuropathological features seen in
VEGFδ/δ mice, such as specific loss of choline-acetyltransfer-
ase-positive motor neurons, the ultrastructural signs of motor
neuron degeneration, axonal spheroids, aberrant neurofilament
inclusions, Wallerian degeneration in peripheral nerves and
selective loss of large myelinated motor axons, are strikingly
similar to those found in mutant SOD1 mice and in ALS
patients. Therefore, the VEGFδ/δ mouse model may be useful to
study the mechanisms of adult-onset motor neuron degenera-
tion and to evaluate therapeutic strategies.
These surprising genetic findings in mice seem to be relevant
for human ALS as well. Although spontaneous mutations of the
hypoxia response element were not detected in ALS individuals,
human subjects homozygous for the −2578A/−1154A/−634G
or −2578A/−1154G/−634G haplotypes in the VEGF gene,
were more common in the population of ALS patients than
healthy individuals [72]. These ‘at-risk’ haplotypes reduced
VEGF gene transcription, impaired IRES-dependent translation,
and interfered with translational initiation of a novel long VEGF
isoform (L-VEGF), resulting in reduced circulating VEGF
levels in vivo. To further characterize the role of VEGF in ALS,
VEGF∂/∂ mice were intercrossed with SOD1G93A mice.
Normally, SOD1G93A mice develop clinical symptoms at the
age of 90 days and die at the age of 130 days. In contrast, VEGF∂/∂
mice only develop symptoms beyond the age of 6 months and
survive for up to 2 years. Notably, double transgenic VEGF∂/∂/
SOD1G93A mice died sooner than single transgenic SOD1G93A
mice, indicating that VEGF also modified motor neuron degen-
eration in the standard mouse model of ALS [72]. By now, our
Fig. 2. Deregulation ofVEGFexpression levels are involved in at least two types ofmotor neuron degeneration. (A)Under normal conditions, hypoxia-induced factors (HIFs)
such as HIF1, co-assemble with transcriptional coactivator CREB-binding proteins (CBP), bind to the hypoxia regulatory element (HRE) in the VEGF promoter and drive
expression of the VEGF gene. (B)Deletion of the HRE region in the VEGF promoter causes a late-onset progressive form ofmotor neuron degeneration, reminiscent to ALS.
(C) Expression of polyglutamine-expanded androgen receptor (AR) traps CBP proteins, thereby interferes with CBP binding to HIF and causes SBMA motorneuropathy.
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in SOD1G93A rats, VEGF levels are reduced before disease onset
and become progressively lower with disease progression [73]. In
humans, low levels of VEGF in the cerebrospinal fluid (CSF) are
also a hallmark of early ALS [74]. In a much smaller association
study by Terry et al., individuals homozygous for the ‘at-risk’
haplotypes exhibited a 3-fold increased risk for ALS [75], whereas
studies performed within the Dutch and UK population reported
that association between the ‘at-risk’ haplotypes and ALS was
lacking [76,77]. Although the precise reason for the lack of
association in this population remains unknown, heterogeneity
between study populations is not entirely uncommon for
association studies and should not, a priori, devaluate a positive
association in other populations. On the other hand, independent
replicative studies should still be encouraged as meta-analysis of
all available published association studies is expected to give a
more robust estimate of the genetic effect [78]. VEGF levels in the
CSF from hypoxaemic patients with ALS are also lower than
VEGF levels from normoxaemic patients with ALS, whereas
hypoxaemic neurological controls display higher VEGF levels
than normoxaemic neurological controls [79]. In ALS patients,
fewer anterior horn cells seem to be capable of expressing normal
expression levels of VEGF and VEGFR2 [80]. All together, these
observations highlight that deregulation of VEGF expression is
implicated in the pathogenesis of ALS in both mice and humans.
To provide a better understanding of the molecular basis of
the VEGF system in motor neuron degeneration, we generated
transgenic mice overexpressing Flk1 in neurons of the adult
nervous system by using the Thy1.2 promoter [81]. The Thy-
Flk1 transgenic mice were fertile, appeared healthy, and theirmotor performance under basal conditions was normal. Inter-
crossing of the Thy-Flk1 transgenic mice with SOD1G93A mice
revealed that the motor performance of the double-transgenic
Thy-Flk1/SOD1G93A transgenic mice deteriorated at a later age
as compared to the single transgenic SOD1G93A mice. Thy-Flk1/
SOD1G93A transgenic mice also lived longer than SOD1G93A
single transgenic mice, revealing that overexpression of Flk1 in
neurons delays the degeneration of spinal motor neurons in
SOD1G93A mice by transmitting survival signals of endogenous
VEGF [81].
8. Role of VEGF in SBMA motor neuronopathy
VEGF has also been implicated in another form of motor
neuron disease, X-linked spinal and bulbar muscular atrophy or
Kennedy's disease, which is caused by a polyglutamine
expansion in the androgen receptor. Ellerby, La Spada and
colleagues produced transgenic mice expressing the expanded
human androgen receptor, which caused a progressive disorder
comprising muscle weakness, atrophy, weight loss and early
death, and manifested histologically by loss of motor neurons
from the anterior horns of the spinal cord and neurogenic
(grouped) muscle fiber atrophy [82]. Motor neurons from these
mice showed reduced viability in cell culture, which was
rescued by treatment with VEGF. In this form of muscular
atrophy, the overexpressed levels of the androgen receptor seem
to interfere with transcription of the VEGF gene by squelching
the transcriptional coactivator CREB-binding protein (CBP),
which is necessary to allow HIF to induce VEGF gene tran-
scription [82] (Fig. 2A, C). Thus, a disturbance in the neuronal
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phenotypically distinct forms of motor neuron disease.
9. Angiogenin, another angiogenic factor linked with ALS
The discovery of the link between VEGF and ALS has also
stimulated interest in evaluating the role that other so-called
angiogenic factors could play in modifying the risk of
developing ALS. Greenway and colleagues focused their
attention on angiogenin (ANG), predicting that, similar to
VEGF, functional abnormalities of ANG would enhance the
risk of ALS [83]. To test their hypothesis, Greenway et al. led a
Euro-American collaborative effort, in which the scientists
sequenced the coding and flanking regions of the ANG gene
[84]. At least seven different heterozygous missense mutations
were identified in the ANG gene from patients with ALS, six of
which were in evolutionary conserved regions of the ANG
gene. The functional consequences of these ANGmutations were
not studied, and therefore, a direct causative link between ANG
mutations and ALS is still lacking.
Unfortunately, we still have a poor understanding of the bio-
logical properties of ANG, and this imposes limitations in our
ability to identify potential molecular mechanisms bywhichANG
mutations are involved in ALS. Several studies have described
ANG as a potent angiogenic factor [85]. Particularly, the angio-
genic effects of VEGF are dependent to some extent, upon the
activity of ANG, i.e., ANG appears to be a downstream effector of
VEGF, at least in endothelial cells [86]. It is therefore reasonable
to speculate that ANG and VEGF might be neuroprotective in
motor neurons via similar or overlapping pathways. Alternatively,
ANG may also have distinctly VEGF-independent modes of
action that result in increased susceptibility to ALS, e.g., by
regulating innate immunity [87] or ribosomal RNA synthesis [88].
10. Finding a therapy for ALS
Despite intensive efforts, ALS remains an incurable disorder.
Riluzole, a glutamate antagonist, is currently the only drug that
has been approved for the treatment of ALS, but it provides only
a marginal therapeutic benefit by retarding the decline in muscle
strength and prolonging survival by only a few months [89].
Neurotrophic factors have been considered for therapy of motor
neuron degeneration, but previous clinical trials have all failed.
Indeed, intrathecal infusion of brain-derived growth factor
(BDNF) and ciliary neurotrophic factor (CNTF), intracerebro-
ventricular (ICV) delivery of glial cell line-derived neurotrophic
factor (GDNF) or systemic administration of BDNF or CNTF
did not result in clinical improvement in ALS patients (reviewed
by [90–92]). When delivered systemically, insulin-like growth
factor (IGF1) marginally reduced disease progression in one but
not in another trial [93,94]. In SOD1G93A mice, leukemia
inhibitory factor (LIF) improved motor neuron survival without
prolonging lifespan in one study but had no effect in another
study [95,96], whereas delivery of BDNF, GDNF, CNTF and
IGF1 recombinant factors has never been evaluated in
SOD1G93A mice. Some of these clinical trials with neurotrophic
agents may have failed because of inappropriate delivery ofthese neurotrophic factors. Indeed, when delivered systemically,
neurotrophic factors often fail to cross the blood–brain barrier
and thus never reach the motor neurons [97]. In addition, these
polypeptides are usually rapidly cleared from the circulation
and may evoke a neutralizing immune reaction after repetitive
injections [97]. When delivered into the CSF, neurotrophins
may also be rapidly cleared into the venous or lymphatic
system, or be unable to penetrate into the surrounding
parenchyma because they are sequestered by cellular receptors
on the ependymal lining—all preventing these neurotrophic
factors to reach the degenerating motor neuron [97]. Optimizing
the appropriate delivery route is thus critical for therapeutic
success.
11. Gene therapy approaches for ALS
Treatment of motor neuron degeneration with neurotrophins
requires chronic delivery. This can be achieved by gene therapy or
repetitive protein delivery. An advantage of viral gene transfer is
that the transduced cells produce a ‘natural’ neurotrophic protein
with a mammalian-type glycosylation pattern, which is not re-
cognized as a foreign antigen. In the past, only viral vectors were
available which were capable of infecting the motor neuron cell
bodies when the viral vector was injected directly into the anterior
horn of the spinal cord. Such invasive surgery is obviously not a
therapeutic option in humans. More recently, improved vectors
have been developed, which facilitate the delivery of neurotrophic
factors to the motor neuron soma [98,99]. These vectors take
advantage of the intrinsic property of the motor neuron to retro-
gradely transport cargo from the nerve terminal via its long axon to
the cell body. The polio, herpes and rabies viruses are capable of
infecting the nerve terminals at the neuromuscular junction.
Thereafter, these neurotropic viruses highjack the axonal transport
system and are thereby capable of reaching the motor neuron cell
body [98,100,101]. Adeno-associated adenoviral vectors (AAV)
and lentiviral vectors pseudotyped with rabies-G envelopes have
been constructed, which are retrogradelly transported via the
axons upon intramuscular injection (as reviewed by Azzouz
[102]). These vectors are particularly relevant for the treatment of
motor neuron disorders, as they offer the opportunity to administer
these vectors via peripheral intramuscular injection.
12. VEGF delivery with the retrogradely transported EIAV
lentiviral vector
To evaluate the therapeutic potential of VEGF for ALS, a
rabies-G pseudotyped EIAV lentiviral vector encoding the human
VEGF gene, EIAV-VEGF, was constructed [99]. After confirming
that this vector was able to produce active VEGF, EIAV vectors
were injected bilaterally into the hindlimb gastrocnemius,
diaphragm, intercostal, facial and tongue muscles of SOD1G93A
mice. VEGF treatment significantly extended the lifespan of these
mice by an average of 38 days. Thereby, VEGF treatment achieved
one of the most effective therapies reported in the field so far,
prolonging survival by as much as 30% [99]. The size of the
observed effect was comparable to that reported for IGF1 when
delivered with AAV2 vectors [98]. Notably, administration of
Fig. 3. VEGF is a pleitrophic factor: VEGF affects motor neurons, microglia,
astrocytes, muscle fibers, blood vessels, oligodendrocytes and Schwann cells.
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prolonging survival by as much as 19 days [99]. When injecting a
similar amount of a rabies-G pseudotyped EIAV vector expressing
GDNF, a negligible increase in survival of 6 days was observed
[99]. These findings indicate a superior specificity and potency of
VEGF over GDNF for ALS. EIAV-VEGF gene transfer was also
well tolerated and did not cause vascular side effects.
13. Recombinant VEGF protein therapy
Though clinical trials with viral vectors are being considered,
the clinical applicability, feasibility, efficacy and safety of gene
therapy for ALS remain to be established. Delivery of recombi-
nant neurotrophic growth factors, on the other hand, is clinically
very attractive, as it offers flexible control of the dose and duration
of the administered protein. Previous clinical trialswith delivery of
a neurotrophic factor failed, however, to show a therapeutic effect,
presumably because the factors were insufficiently active, immu-
nogenic, rapidly cleared or inappropriately delivered. By using
osmotic mini-pumps implanted subcutaneously on the back of
SOD1G93A rats, another rodentmodel of ALS, wewere capable of
delivering the recombinant protein continuously via a catheter
stereotactically implanted in the left lateral ventricles of rats
for more than 100 days [81]. Distribution studies revealed
that 125I-VEGF, after bolus injection into the left lateral ventricle,
diffused from the CSF into the parenchyme of the brain and spinal
cord and reached the motor neurons, where it remained intact for
several hours [81].
Compared to rats treated with artificial cerebrospinal fluid
(aCSF), SOD1G93A rats receiving 0.2 μg VEGF/kg/day exhibited
a delayed disease onset, an improved motor performance, a
longer spontaneous activity and prolonged survival [81]. When
scoring spontaneous activity, for instance, VEGF-treated animals
consistently performed better than controls for as long as 35 to
42 days, whereas survival of SOD1G93A rats was prolonged by
22 days after VEGF treatment. SOD1G93A rats tolerated the
VEGF treatment well without adverse effects. To evaluate
whether ICV delivery of VEGF would be capable of prolonging
survival when initiated at the time of disease onset, 0.2 μg VEGF/
kg/daywas administered from 85 days of age, when the first signs
of motor impairment emerged. Despite the very rapidly
progressing disease course of this model, treatment of
SOD1G93A rats with ICVdeliveredVEGF significantly improved
survival by 10 days [81]. VEGF treatment at 60 days also changed
the disease subtype from a severe to a much milder form. Indeed,
significantly fewer SOD1G93A rats suffered from the severe fore-
limb (FL) onset type of disease after VEGF than aCSF delivery.
Compared to aCSF-treated rats with hindlimb (HL)- or FL-onset,
VEGF-treated rats survived 17 or 27 days longer, respectively
[81]. This is a relevant finding, as involvement of brain stem and
cervical disease results in a worse prognosis in both rats and
humans. The more pronounced therapeutic effect of VEGF on
forelimb than hindlimbmuscles is likely attributable to the higher
VEGF levels in the bulbar/cervical than in the lumbar spinal cord
upon ICV delivery.
Recently, systemic delivery of recombinant VEGF was also
shown to prolong the survival of SOD1G93A mice. As VEGF isunlikely to cross the blood–brain barrier, these data may possibly
suggest that VEGF affects motor neuron survival indirectly via
effects on the vasculature [103].
14. Therapeutic mechanisms of VEGF
VEGFhas distinct biological activities, which differ from those
of other neurotrophic factors. Similar to IGF1, VEGF has
pleiotropic effects on various different types of neuronal and
glial cells, stimulates neurogenesis, is axonally transported in an
antero- and retrograde direction and stimulates neural perfusion
[41,45,81]—all these effects might have contributed to promote
motor neuron survival in ALS models (Fig. 3). In addition, while
VEGF and other neurotrophins are capable of affecting motor
neurons, their importance in the pathogenesis of ALS may differ
substantially. Indeed, even though over- or under-expression of
BDNF, GDNF, CNTF or LIF affected motor neurons during
development and injured motor neurons after birth, and although
adenoviral gene transfer of some of these factors stimulated motor
neuron survival inALSmousemodels, loss of these neurotrophins
did not cause adult-onset ALS-like motor neuron degeneration
and paralysis in mice.
15. Role for VEGF in acute neurological diseases
VEGF has also been implicated in several acute neurological
disorders, in which it exerts both positive and negative effects. In
addition to its protective effects, VEGF expression has also been
implicated in blood–brain barrier breakdown after cerebral
ischemia [104,105], and as an inflammatory mediator, it may
also contribute to inflammatory responses under certain disorders.
All these activities of VEGF make it challenging to determine
whether VEGF will aggravate or improve clinical outcome of
experimental paradigms, and whether these effects are due to its
neuro-, glio- or endotheliotrophic activities.
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barrier occurs acutely, followed by leakage of plasma proteins into
the brain parenchyma (edema) and infiltration of inflammatory
cells into the infarcted region. VEGF may stimulate vascular
leakage and vessel permeability and have detrimental effects after
cerebral ischemia. Early post-ischemic administration of VEGF
resulted in prominent brain edema, hemorrhagic transformation
of the infarct, and enlargement of the ischemic lesion [106],
whereas intraperitoneal administration of a fusion protein that
sequesters VEGF reduced infarct size in another study [107],
indicating that the effects of VEGF in cerebral ischaemia can
indeed be detrimental. Likewise, acute intraparenchymal injection
of VEGF after spinal cord injury also resulted in exacerbation of
the spinal cord lesion volume [108]. On the other hand, VEGF
expression is strongly induced after acute focal cerebral ischemia,
as early as 1–3 h, and peaks at 24–48 h after onset of ischemia
[109–112], suggesting that VEGF may have beneficial effects as
well. Indeed, administration of VEGF at 48 h after stroke
protected neurons and improved neurological outcome [113,114].
From7 days after the stroke, cerebralmicrovascular perfusion and
vessel architecture in the ischemic penumbra were increased and
led to improved vascular perfusion. In a model of severe spinal
cord ischemia induced by clamping the thoracic vessels, most of
the ventral horn neurons degenerate leading to complete paralysis
in mice [115]. VEGF treatment rescued some of the motor
neurons from death in this model and resulted in a significantly
improved neurological outcome [115]. After spinal cord injury,
Widenfalk et al. also observed beneficial effects of VEGF
delivery attributable to angio- and neuroprotective effects as
revealed by the increased density of blood vessels and the reduced
number of apoptotic cells within the lesion [116]. Remarkably,
intracerebroventricular administration of VEGF also enhanced
neurogenesis in a stroke model as the number of BrdU-positive
labeled cells of neuronal lineage was increased after 4 weeks
[113,114]. Like VEGF, its homologue VEGF-B (Fig. 1) also
seems to exert a neuroprotective effect in cerebral ischaemia [117]
as the infarct volume after cerebral ischemia was increased in
VEGF-B-knockout compared with wild-type mice, and neuro-
logical function was more impaired. Notably, VEGF-B also
stimulated neurogenesis [118]. Thus, in animal models of stroke,
early delivery of VEGF (within 1 h of onset) worsens outcome by
increasing vascular permeability and brain edema, whereas late
administration of VEGF (48 h after onset) is beneficial. How
exactly VEGF exerts its protective effects in stroke still remains to
be further established, but it most likely involves a combination of
neuroprotection, vascular perfusion and neurogenesis.
Blood–brain barrier breakdown, edema and inflammation are
also observed after seizures, although the magnitude of these
events is substantially milder than seen after cerebral ischemia
[119]. Because of these similarities, mediators of post-ischemic
injury are now also being investigated in seizures. One day after a
status epilepticus, VEGF expression is dramatically increased
both in neurons and glial cells of the hippocampus and limbic
cortex [119]. VEGF also protects cultured hippocampal neurons
against glutamate excitotoxicity [120], whereas intra-hippocam-
pal infusion of VEGF appears to protect hippocampal neurons
from seizure-induced damage [119]. To examine the effect ofVEGF on the intrinsic properties and synaptic responses of
hippocampal neurons, VEGF was administered to adult rat hip-
pocampal slices. VEGF reduced the amplitude of excitatory re-
sponses elicited after stimulation and was able to suppress
epileptiform activity in epileptic rats, but not in normal rat slices
[121]. VEGF may thus also play a role to decrease epileptiform
activity in the epileptic brain.
16. VEGF in other neurodegenerative disorders
VEGF is also important for diseases of the peripheral nervous
system. Intramuscular administration of plasmid DNA encoding
VEGF improved nerve function in rats with diabetic (streptozo-
tocin-induced) polyneuropathy [122], and intramuscular delivery
of naked VEGFDNA had a similar effect in rabbits with ischemic
neuropathy [54]. Recently, Fink and colleagues administered a
replication-defective herpes simplex virus (HSV) vector expres-
sing VEGF intramuscularly to mice with streptozotocin neurop-
athy and found preservation of nerve fibers, increased sensory
nerve amplitudes and thermal pain perception, improved auto-
nomic function and greater nerve vascularity [123]. An additional
study demonstrated that VEGF application via matrigel in a
silicone sciatic nerve chamber enhanced myelin axon counts by
78% and significantly improved motor performance [124]. In
these experiments, VEGF increased angiogenesis in the chamber
and enhanced Schwann cell proliferation and migration. Though
it is attractive to postulate a direct neuroregenerative role ofVEGF
in these studies, it is difficult in many of these examples to assess
whether neural repair or neuroprotection are the results of a direct
neurotrophic effect or are secondary to VEGF-driven angiogen-
esis and hence improved perfusion of the ischemic region.
Alzheimer's disease (AD) is characterized by amyloid plaques,
neurofibrillary tangles, cerebral hypoperfusion and amyloid an-
giopathy. The observation that cerebral hypoperfusion precedes
the onset of clinical symptoms in AD suggests that chronic brain
hypoperfusion increases the risk for AD [125]. Amyloid-β has
direct effects on the cerebral vasculature: it causes vasoconstric-
tion, reduces the blood flow, and even induces endothelial cell
damage. Furthermore, VEGF co-localizes with and binds
amyloid-β plaques in the brains of AD patients [126]. Such a
deposition of VEGF in plaques may reduce the availability of
VEGF and thereby causally contribute to cerebral hypoperfusion
in AD and further aggravate memory decline. Other studies have
also suggested that cerebral microvascular amyloid accumulation
is a better correlate with dementia than parenchymal amyloid
plaques [127], indicating that AD has also a neurovascular com-
ponent. Interestingly, the −2578AVEGF allele, which correlates
with reduced VEGF expression levels in plasma and serum, also
confers an increased risk for patients with Alzheimer disease in
one study [128], but not in another [129]. Others reported that
expression levels of VEGF in the CSF of AD patients are in-
creased and that VEGF immunoreactivity is also enhanced around
perivascular astrocytes andwalls of cerebral vessels in the subjects
with AD when compared to elderly [130,131]. However, since
cerebral hypoperfusion leads to cerebral ischemia, which
increases VEGF expression levels, increasing VEGF expression
levels may be a compensatory repair mechanism to counteract
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Although little is known about the involvement of VEGF in AD,
recent studies on VEGF and AD suggest that VEGF may indeed
contribute to neurodegeneration and vascular dysfunction in AD.
There is some evidence suggesting that VEGF could have a
protective role against the selective degeneration of dopaminergic
neurons in Parkinson's disease. Unilateral implantation of encap-
sulated VEGF-producing cells into the striatum of adult rats,
1 week before administration of 6-OHDA, reduces amphetamine-
induced rotational behavior, augments tyrosine-hydroxylase-
positive neurons and fibers, and increases vascularization and
proliferation of glia [132,133]. Furthermore, a single bolus injec-
tion of VEGF into the striatum of unilaterally 6-OHDA lesioned
rats before transplantation of solid ventral mesencephalic grafts
into the same striatum results in more homogeneous distribution
of small blood vessels throughout the graft and accelerated re-
covery of amphetamine-induced rotational asymmetry [134];
therefore, VEGF may also improve the function of fetal ventral
mesencephalic tissue grafts.
All these studies suggest that VEGF might have therapeutic
potential for several neurological diseases. However, when con-
sidering VEGF therapy, careful optimization of the VEGF dose
will be required to avoid hemangioma, edema formation and
ventriculomegaly, an increase in tumor angiogenesis and tumor-
associated intracranial hemorrhage.
17. Conclusion
Originally discovered in 1983, VEGFhas come forth as the key
mediator of angiogenesis in health and disease. Only recently have
direct effects of VEGF on neuronal cell types been described. It is
now evident that VEGF is implicated in ALS, but also in other
neurodegenerative disorders. Evidence that VEGF gene transfer
or protein delivery improves the outcome of ALS is most
promising.
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